Summary:
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safetyand Efficacyof Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance 30 to<60 mL/min Who Have Not Achieved Target Serum Uric Acid Levels on an XOI Alon
Qualified Participants Must:
• Have been diagnosed with gout
•
Have problems with kidney function
•
Either taking allopurinol, febuxostat, or uloric
Qualified Participants May Receive:
Compensation for travel visits
Free medications
Free physician evaluations
fFee blood tests and imaging tests